Please assess the completion status of the following clinical trial:

Trial Title: A Study of Alpharadin With Docetaxel in Patients With Bone Metastasis From Castration-Resistant Prostate Cancer (CRPC)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically or cytologically confirmed adenocarcinoma of the prostate.~* Two or more bone metastases (hot spots) confirmed by bone scintigraphy within 8 weeks prior to study entry~* Known castration-resistant disease~* Karnofsky Performance Status (KPS): ≥70% within 14 days before start of study treatment (ECOG 1)~* Life expectancy at least 6 months.~* Acceptable hematology and serum biochemistry screening values~* Eligible for use of docetaxel according to the product information (package insert or similar).~Exclusion Criteria:~* Has received an investigational therapeutic drug within the last 4 weeks prior to start of study treatment, or is scheduled to receive one during the treatment period.~* Has received external radiotherapy within the last 4 weeks prior to start of study treatment.~* Has an immediate need for radiotherapy.~* Has received prior hemibody external radiotherapy .~* Has received systemic radiotherapy (e.g. samarium, strontium etc.) for the treatment of bone metastases.~* Has received cytotoxic chemotherapy within the last 4 weeks prior to start of study treatment, or has not recovered to grade 1 or 0 from adverse events due to cytotoxic chemotherapy administered more than 4 weeks earlier.~* Has received more than ten previous infusions of docetaxel.~* Previous known experience of grade ≥ 3 docetaxel related toxicities or docetaxel toxicity related dose interruption or discontinuation.~* Previous use of G-CSF for persistent neutropenia after docetaxel treatment.~* Has received blood transfusion or erythropoietin (EPO) within the last 4 weeks prior to start of study treatment.~* Has received prior treatment with Alpharadin.~* Malignant lymphadenopathy exceeding 3 cm in short-axis diameter.~* Symptomatic nodal disease, i.e. scrotal, penile or leg edema.~* Visceral metastases from CRPC (\>2 lung and/or liver metastases \[size ≥2cm\]), as assessed by CT scan or MRI of the chest/abdomen/pelvis within the last 8 weeks prior to start of study treatment.~* Uncontrolled loco-regional disease.~* Other primary tumor (other than CRPC) including haematological malignancy present within the last 5 years (except non-melanoma skin cancer or low-grade superficial bladder cancer).~* Has imminent or established spinal cord compression based on clinical findings and/or MRI.~* Unmanageable fecal incontinence

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Radium-223 dichloride (Xofigo, BAY88-8223) + docetaxel (Type: EXPERIMENTAL): Alpharadin (Radium-223 dichloride) is administered intravenously as a bolus injection. In the randomized phase IIa part of the protocol, the dose established in the dose-escalation part of the protocol (Phase I) will be used, i.e. 5 doses of 50 kBq/kg b.w. every 6 weeks in combination with the approved step-down dose of docetaxel (60 mg/m\^2) administered intravenously every 3 weeks with 5 mg prednisone twice a day continuously and pre-medication with dexamethasone.
- Docetaxel (Type: ACTIVE_COMPARATOR): Docetaxel (75 mg/m2) will be administered intravenously every 3 weeks with 5 mg prednisone twice a day continuously and pre-medication with dexamethasone. Step-down to 60 mg/m\^2 is allowed as per the approved docetaxel label.

Based on this trial design, predict the completion outcome and termination type (if applicable).